Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study

Charles V. Pollack^*, Richard A Bernstein, Robert Dubiel, Paul Reilly, Fredrik Gruenenfelder, Menno V. Huisman, Chak Wah Kam, Eva Kleine, Jerrold H. Levy, Frank W. Sellke, Thorsten Steiner, Anastasia Ustyugova, Jeffrey I. Weitz

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

3 results
- Title
- Start date(ascending)

Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study
Pollack, C. V. (Creator), Bernstein, R. A. (Creator), Dubiel, R. (Creator), Reilly, P. (Creator), Gruenenfelder, F. (Creator), Huisman, M. V. (Creator), Kam, C. (Contributor), Kleine, E. (Creator), Levy, J. H. (Creator), Sellke, F. W. (Creator), Steiner, T. (Creator), Ustyugova, A. (Creator) & Weitz, J. I. (Creator), figshare, 2017
DOI: 10.6084/m9.figshare.4476206, https://figshare.com/articles/Healthcare_resource_utilization_in_patients_receiving_idarucizumab_for_reversal_of_dabigatran_anticoagulation_due_to_major_bleeding_urgent_surgery_or_procedural_interventions_interim_results_from_the_RE-VERSE_AD_sup_sup_study/4476206
Dataset
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study
Pollack, C. V. (Creator), Bernstein, R. A. (Creator), Dubiel, R. (Creator), Reilly, P. (Creator), Gruenenfelder, F. (Creator), Huisman, M. V. (Creator), Kam, C. (Contributor), Kleine, E. (Creator), Levy, J. H. (Creator), Sellke, F. W. (Creator), Steiner, T. (Creator), Ustyugova, A. (Creator) & Weitz, J. I. (Creator), Taylor & Francis, 2017
DOI: 10.6084/m9.figshare.4476206.v2, https://tandf.figshare.com/articles/dataset/Healthcare_resource_utilization_in_patients_receiving_idarucizumab_for_reversal_of_dabigatran_anticoagulation_due_to_major_bleeding_urgent_surgery_or_procedural_interventions_interim_results_from_the_RE-VERSE_AD_sup_sup_study/4476206/2
Dataset
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study
Pollack, C. V. (Creator), Bernstein, R. A. (Creator), Dubiel, R. (Creator), Reilly, P. (Creator), Gruenenfelder, F. (Creator), Huisman, M. V. (Creator), Kam, C. (Contributor), Kleine, E. (Creator), Levy, J. H. (Creator), Sellke, F. W. (Creator), Steiner, T. (Creator), Ustyugova, A. (Creator) & Weitz, J. I. (Creator), figshare, 2016
DOI: 10.6084/m9.figshare.4476206.v1, https://figshare.com/articles/Healthcare_resource_utilization_in_patients_receiving_idarucizumab_for_reversal_of_dabigatran_anticoagulation_due_to_major_bleeding_urgent_surgery_or_procedural_interventions_interim_results_from_the_RE-VERSE_AD_sup_sup_study/4476206/1
Dataset